Adenosine receptor agonists with high potency and selectivity and a moderate duration of action have been targeted as potential drugs for the therapy of cardiac arrhythmias such as PSVT. A series of related xanthines that block the adenosine receptor will also be prepared. Compounds of this type act as diureics and have potential application in the treatment of congestive heart failure.
|Effective start/end date
|1/10/01 → …
- Australian Research Council (ARC): A$86,472.00